Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CEACAM1 monoclonal antibody
- Development stage
- Preclinical
- Lead developer
- Trellis Bioscience
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intraperitoneal
01
Overview
Trellis Bioscience is developing a native human monoclonal antibody targeting CEACAM1 (carcinoembryonic antigen-related cellular adhesion molecule 1) for the treatment of cancer. Discovered using the company's proprietary CellSpot platform, which identifies high-affinity antibodies from the memory B-cells of healthy human donors, this antibody functions as an immune checkpoint modulator. CEACAM1 is an inhibitory molecule expressed on various tumor types as well as on T cells and Natural Killer (NK) cells. Its interaction suppresses immune cell activation and allows tumors to evade immune surveillance. By blocking these immunosuppressive interactions, the antibody aims to enhance anti-tumor immune responses. The program is currently in preclinical development.
- Other names
- anti-CEACAM1 mAbanti-CEACAM-1 mAbanti-CEACAM 1 mAbCEACAM1-monoclonal antibodyCEACAM-1-monoclonal antibodyCEACAM 1-monoclonal antibody
02
Targets
CEACAM1
Beyond the preview
Go deeper on anti-CEACAM1 monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CEACAM1 monoclonal antibody.